Belgium
Advancing healthcare, to better the lives of individuals, patients and societies. Experienced leader, working within the pharmaceutical and biotechnology industry. Expertise in the areas of vaccination and infectious diseases (HIV, RSV, Influenza, Shingles, TBE, Tuberculosis, Pertussis). Graduated from IE Business School with an MBA, combining business acumen with scientific knowledge, to ensure the right solution is developed and reaches patients in a sustainable way.
Dual role: - Led the development organisation for the newly acquired chikungunya vaccine from Emergent, with direct reporting line and accountability for RA, clinical operations, clinical strategy, biostatistics, data management and project management - Program Lead, responsible for leading the successful completion of the Ph3 studies, file, approval, manufacture and launch preparation of the vaccine. Achieved parallel review and approval for both BLA/MAA under priority review and accelerated assessment.
Influenza vaccine portfolio & adult vaccination
Tdap / Tdap-IPV vaccine portfolio (Boostrix)
Two-year leadership development programme for high-potential professionals, with rotations in various business units Commercial manager EU region (6 months) Role focused on optimising GSK Vaccine’s portfolio performance at a regional level Medical affairs (1 year) Involved in the launch of GSK’s shingles vaccine Shingrix Value strategy (6 months) Analysed and developed the investment rationale for early discovery/pre-clinical R&D projects
Part of the PreDiCT-TB consortium, a public-private partnership to treat and prevent Tuberculosis. Developed a novel drug screening platform for anti-tuberculosis compounds
Analysed data sets of genomic and transcriptomic information to determine key survival pathways in Mycobacteria Biosafety level category III trained